CNS Pharmaceuticals, Inc. financial data

Symbol
CNSP on Nasdaq
Industry
Pharmaceutical Preparations
Location
2100 West Loop South, Suite 900, Houston, TX
State of incorporation
NV
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 102 % +10.5%
Debt-to-equity 2.41K %
Return On Equity -7.38K % -122%
Return On Assets -294 % +30.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.94M shares -72.3%
Common Stock, Shares, Outstanding 1.41M shares
Entity Public Float 8.78M USD 0%
Common Stock, Value, Issued 1.41K USD
Weighted Average Number of Shares Outstanding, Basic 382K shares -74.6%
Weighted Average Number of Shares Outstanding, Diluted 382K shares -74.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 9.29M USD -34.1%
General and Administrative Expense 5.61M USD +17.7%
Operating Income (Loss) -14.9M USD +21%
Nonoperating Income (Expense) 44.1K USD +218%
Net Income (Loss) Attributable to Parent -14.9M USD +21.2%
Earnings Per Share, Basic -38.9 USD/shares
Earnings Per Share, Diluted -38.9 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.46M USD +1078%
Assets, Current 8.66M USD +444%
Property, Plant and Equipment, Net 6.01K USD +21.7%
Assets 8.7M USD +412%
Accounts Payable, Current 3.57M USD +627%
Accrued Liabilities, Current 260K USD -5.94%
Liabilities, Current 2.52M USD -58.8%
Liabilities 2.52M USD -58.8%
Retained Earnings (Accumulated Deficit) -84.4M USD -21.4%
Stockholders' Equity Attributable to Parent 6.18M USD
Liabilities and Equity 8.7M USD +412%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.19M USD +33.8%
Net Cash Provided by (Used in) Financing Activities 3.46M USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 1.41M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.46M USD +1078%
Interest Paid, Excluding Capitalized Interest, Operating Activities 6.63K USD +21.9%
Deferred Tax Assets, Valuation Allowance 15.3M USD +19.9%
Depreciation 818 USD -36%
Deferred Tax Assets, Operating Loss Carryforwards 7.92M USD +18.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Additional Paid in Capital 90.6M USD +39.1%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 15K USD +51.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%